Characteristics | Ā | GIB (nā=ā55) | No GIB (nā=ā165) | p-value |
---|---|---|---|---|
Sex, n (%) | Male | 41 (74.5%) | 104 (63.0%) | 0.12 |
Age, averageāĀ±āSD | Ā | 47.31āĀ±ā10.45 | 43.83āĀ±ā10.62 | 0.04 |
BMI, kg/m2 | Ā | 22.40āĀ±ā3.68 | 21.61āĀ±ā3.16 | 0.13 |
Systolic blood | ||||
Pressure, mmHg | Ā | 128āĀ±ā24 | 127āĀ±ā13 | 0.72 |
Heart rate (/min) | Ā | 92āĀ±ā19 | 87āĀ±ā15 | 0.16 |
Anticoagulant drugs usage, n (%) | Negative | 49 (89.1%) | 158 (95.8%) | 0.07 |
Intravenous hormone usage,n (%) | Negative | 36 (65.5%) | 147 (89.1%) | ā<ā0.001 |
Hemoglobin, g/L | Ā | 111.46āĀ±ā29.85 | 120.69āĀ±ā24.73 | 0.03 |
Platelet, 109/L | Ā | 179.98āĀ±ā84.18 | 201.60āĀ±ā59.28 | 0.04 |
INR | Ā | 1.06āĀ±ā0.25 | 0.98āĀ±ā0.13 | ā<ā0.001 |
Urea nitrogen, mmol/L | Ā | 13.04āĀ±ā8.42 | 9.91āĀ±ā6.14 | ā<ā0.001 |
Creatinine,Ī¼mol/L | Ā | 170.89āĀ±ā80.33 | 142.01āĀ±ā87.85 | ā<ā0.001 |
eGFR, ml / (min * 1.73m2) | Ā | 48.35āĀ±ā26.95 | 58.31āĀ±ā28.13 | ā<ā0.001 |
Albumin, g/L | Ā | 34.48āĀ±ā5.25 | 40.00āĀ±ā5.52 | ā<ā0.001 |
Calcineurin inhibitors, n (%) | Tacrolimus | 47 (85.5%) | 153 (92.7%) | 0.10 |
Ā | Cyclosporine A | 8 (14.5%) | 12 (7.3%) | Ā |
Complication | ||||
Diabetes, n (%) | No | 47 (85.5%) | 155 (93.9%) | 0.05 |
Viral hepatitis (HBV/HCV), n (%) | Negative | 43 (78.2%) | 160 (97.0%) | ā<ā0.001 |
Pulmonary infection, n (%) | Negative | 34 (61.8%) | 116 (70.3%) | 0.24 |
Cardio-cerebrovascular disease, n (%) | Negative | 48 (87.3%) | 161 (97.6%) | ā<ā0.001 |
Malignant tumor, n (%) | Negative | 52 (94.5%) | 160 (97.0%) | 0.41 |
Outcome, n (%) | Mortality | 16 (29.1%) | 9 (5.5%) | 0.03 |